A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 9 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 12th largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 12th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 5 started in 2014.
This study's enrollment of 865 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 13th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 22nd registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Also known as: Pneumo 23™
Number of Subjects With a Vaccine Response for Anti-gE Antibodies
Vaccine response rate for anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the Co-Ad group. Vaccine response defined as : For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration
Time frame: At Month 3
Anti-glicoprotein E (gE) Antibody Concentrations
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations and expressed as milli international units per milliliter (mIU/mL).
Time frame: At one month post-dose 2 (Month 3 for the Co-Ad Group and Month 5 for the Control Group)
Anti-pneumococcal Antibody Titers
Anti-pneumococcal antibody titers were presented as geometric mean titers (GMTs) for the 12 following serotypes as determined by Opsonophagocytic Assay (OPA): 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
Time frame: At one month post-dose (Month 1)
Adjusted Ratios of Geometric Mean Titers (GMTs) Between Groups
The Adjusted ratios of GMTs between groups (Control group and Co-Ad group) were presented for each individual pneumococcal conjugate serotype Opsonophagocytic Activity (OPA).
Time frame: At 1 month after vaccination
Adjusted GMCs Between Groups
The Adjusted ratios of GMCs between groups (Control group and Co-Ad group) was presented for anti-gE antibody ELISA concentrations
Time frame: At 1 month after last vaccine dose
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses.
Time frame: Within 7 days (Days 0 - 6) after each vaccination
Number of Subjects With Solicited Local Symptoms, Across Doses, by Vaccine
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within 7 days (Days 0 - 6) after vaccination
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Any Solicited Local and General Symptoms
The Co-Ad Group received only 2 vaccine doses, hence the number of participants for the Dose 3 categories in this group is 0.
Time frame: Within 7 days (Days 0 - 6) after each vaccination
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: From the first dose up to 30 days post last vaccination period
Number of Subjects With Serious Adverse Events (SAEs) [From the First Dose up to 30 Days Post Last Vaccination Period]
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From the first dose up to 30 days post last vaccination period
Number of Subjects With Serious Adverse Events (SAEs) [From 30 Days Post Last Vaccination up to Study End]
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From 30 days post last vaccination up to study end
Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [From First Vaccination up to 30 Days Post Last Vaccination]
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From first vaccination up to 30 days post last vaccination (Month 0 - Month 3 for the Co-Ad Group & Month 0 - Month 5 for the Control Group)
Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End]
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: During the period starting after 30 days post last vaccination up to study end (Month 3 - Month 14 for the Co-Ad Group & Month 5 - Month 16 for the Control Group)
| Milestone | Co-Ad Group | Control Group |
|---|---|---|
| Started | 432 | 433 |
| Completed | 423 | 419 |
| Not completed | 9 | 14 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Migrated from study area | 0 | 2 |
Vaccine response rate for anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the Co-Ad group. Vaccine response defined as : For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration
| Participants | Co-Ad Group |
|---|---|
| Number of Subjects With a Vaccine Response for Anti-gE Antibodies | 394 |
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations and expressed as milli international units per milliliter (mIU/mL).
| mIU/mL | Co-Ad Group | Control Group |
|---|---|---|
| Anti-glicoprotein E (gE) Antibody Concentrations | 49918.0 (47143.0 to 52856.3) | 50327.9 (47200.4 to 53662.7) |
Anti-pneumococcal antibody titers were presented as geometric mean titers (GMTs) for the 12 following serotypes as determined by Opsonophagocytic Assay (OPA): 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| MOPA-1 | 65.1 (54.2 to 78.1) | 68.6 (56.9 to 82.7) |
| MOPA-9V | 1898.4 (1618.1 to 2227.2) | 1991.3 (1716.0 to 2310.8) |
| MOPA-14 | 2629.4 (2297.4 to 3009.3) | 2612.8 (2230.7 to 3060.3) |
| MOPA-3 | 106.7 (92.6 to 122.9) | 107.4 (92.7 to 124.4) |
| MOPA-4 | 1079.4 (924.0 to 1260.9) | 1328.8 (1141.0 to 1547.6) |
| MOPA-5 | 161.4 (134.6 to 193.6) | 149.5 (123.5 to 181.0) |
| MOPA-6B | 1619.0 (1354.5 to 1935.0) | 1564.4 (1303.5 to 1877.6) |
| MOPA-7F | 2352.5 (2049.5 to 2700.3) | 2460.4 (2128.7 to 2843.8) |
| MOPA-18C | 1077.4 (921.1 to 1260.2) | 1076.0 (918.2 to 1260.9) |
| MOPA-19A | 1349.6 (1152.1 to 1580.8) | 1573.1 (1350.7 to 1832.2) |
| MOPA-19F | 904.3 (779.6 to 1049.0) | 953.0 (814.8 to 1114.6) |
| MOPA-23F | 431.4 (356.1 to 522.7) | 367.3 (300.8 to 448.5) |
The Adjusted ratios of GMTs between groups (Control group and Co-Ad group) were presented for each individual pneumococcal conjugate serotype Opsonophagocytic Activity (OPA).
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| MOPA-1 | 67.6 (56.9 to 80.2) | 65.6 (55.2 to 77.9) |
| MOPA-3 | 105.0 (92.2 to 119.5) | 108.9 (95.7 to 124.1) |
| MOPA-4 | 1264.1 (1089.9 to 1466.2) | 1117.2 (963.1 to 1296.1) |
| MOPA-5 | 152.6 (129.1 to 180.3) | 159.8 (135.1 to 188.9) |
| MOPA-6B | 1536.8 (1307.9 to 1805.7) | 1666.6 (1418.0 to 1958.6) |
| MOPA-7F | 2491.3 (2179.8 to 2847.5) | 2324.7 (2033.3 to 2657.9) |
| MOPA-9V | 1911.8 (1651.6 to 2212.9) | 1970.3 (1700.9 to 2282.3) |
| MOPA-14 | 2610.1 (2281.6 to 2986.0) | 2678.1 (2339.4 to 3065.8) |
| MOPA-18C | 1040.9 (902.7 to 1200.4) | 1099.8 (952.8 to 1269.6) |
| MOPA-19A | 1558.6 (1361.8 to 1783.8) | 1350.5 (1180.0 to 1545.7) |
| MOPA-19F | 938.2 (814.6 to 1080.7) | 914.1 (793.4 to 1053.3) |
| MOPA-23F | 372.8 (316.0 to 439.8) | 419.1 (354.9 to 494.9) |
The Adjusted ratios of GMCs between groups (Control group and Co-Ad group) was presented for anti-gE antibody ELISA concentrations
| mIU/mL | Co-Ad Group | Control Group |
|---|---|---|
| Adjusted GMCs Between Groups | 49569.0 (46641.4 to 52680.4) | 50474.5 (47497.4 to 53638.2) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 344 | 169 |
| Grade 3 Pain, Dose 1 | 46 | 5 |
| Any Redness, Dose 1 | 182 | 31 |
| Grade 3 Redness, Dose 1 | 15 | 2 |
| Any Swelling, Dose 1 | 99 | 21 |
| Grade 3 Swelling, Dose 1 | 4 | 1 |
| Any Pain, Dose 2 | 298 | 290 |
| Grade 3 Pain, Dose 2 | 35 | 28 |
| Any Redness, Dose 2 | 146 | 129 |
| Grade 3 Redness, Dose 2 | 15 | 4 |
| Any Swelling, Dose 2 | 79 | 67 |
| Grade 3 Swelling, Dose 2 | 4 | 2 |
| Any Pain, Dose 3 | 0 | 293 |
| Grade 3 Pain, Dose 3 | 0 | 32 |
| Any Redness, Dose 3 | 0 | 136 |
| Grade 3 Redness, Dose 3 | 0 | 8 |
| Any Swelling, Dose 3 | 0 | 74 |
| Grade 3 Swelling, Dose 3 | 0 | 3 |
| Any Pain, Across Doses | 372 | 357 |
| Grade 3 Pain, Across Doses | 68 | 49 |
| Any Redness, Across Doses | 233 | 194 |
| Grade 3 Redness, Across Doses | 27 | 12 |
| Any Swelling, Across Doses | 137 | 115 |
| Grade 3 Swelling, Across Doses | 7 | 6 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Any Pain, GSK1437173A, Across Doses | 369 | 343 |
| Any Pain, Pneumovax 23, Across Doses | 223 | 169 |
| Any Redness, GSK1437173A, Across Doses | 223 | 186 |
| Any Redness, Pneumovax 23, Across Doses | 69 | 31 |
| Any Swelling, GSK1437173A, Across Doses | 129 | 108 |
| Any Swelling, Pneumovax 23, Across Doses | 36 | 21 |
Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Any Fatigue, Dose 1 | 194 | 87 |
| Grade 3 Fatigue, Dose 1 | 27 | 3 |
| Related Fatigue, Dose 1 | 175 | 81 |
| Any Gastrointestinal symptoms, Dose 1 | 76 | 31 |
| Grade 3 Gastrointestinal symptoms, Dose 1 | 6 | 1 |
| Related Gastrointestinal symptoms, Dose 1 | 67 | 28 |
| Any Headache, Dose 1 | 156 | 72 |
| Grade 3 Headache, Dose 1 | 15 | 3 |
| Related Headache, Dose 1 | 141 | 64 |
| Any Myalgia, Dose 1 | 187 | 87 |
| Grade 3 Myalgia, Dose 1 | 29 | 5 |
| Related Myalgia, Dose 1 | 177 | 82 |
| Any Shivering, Dose 1 | 91 | 27 |
| Grade 3 Shivering, Dose 1 | 12 | 1 |
| Related Shivering, Dose 1 | 86 | 26 |
| Any Temperature, Dose 1 | 69 | 12 |
| Grade 3 Temperature, Dose 1 | 1 | 1 |
| Related Temperature, Dose 1 | 67 | 11 |
| Any Fatigue, Dose 2 | 191 | 124 |
| Grade 3 Fatigue, Dose 2 | 29 | 11 |
| Related Fatigue, Dose 2 | 174 | 109 |
| Any Gastrointestinal symptoms, Dose 2 | 61 | 38 |
| Grade 3 Gastrointestinal symptoms, Dose 2 | 6 | 4 |
| Related Gastrointestinal symptoms, Dose 2 | 52 | 29 |
| Any Headache, Dose 2 | 141 | 104 |
| Grade 3 Headache, Dose 2 | 19 | 9 |
| Related Headache, Dose 2 | 124 | 85 |
| Any Myalgia, Dose 2 | 182 | 124 |
| Grade 3 Myalgia, Dose 2 | 25 | 11 |
| Related Myalgia, Dose 2 | 171 | 119 |
| Any Shivering, Dose 2 | 83 | 30 |
| Grade 3 Shivering, Dose 2 | 14 | 3 |
| Related Shivering, Dose 2 | 78 | 25 |
| Any Temperature, Dose 2 | 67 | 30 |
| Grade 3 Temperature, Dose 2 | 0 | 0 |
| Related Temperature, Dose 2 | 63 | 26 |
| Any Fatigue, Dose 3 | 0 | 174 |
| Grade 3 Fatigue, Dose 3 | 0 | 22 |
| Related Fatigue, Dose 3 | 0 | 166 |
| Any Gastrointestinal symptoms, Dose 3 | 0 | 47 |
| Grade 3 Gastrointestinal symptoms, Dose 3 | 0 | 3 |
| Related Gastrointestinal symptoms, Dose 3 | 0 | 46 |
| Any Headache, Dose 3 | 0 | 144 |
| Grade 3 Headache, Dose 3 | 0 | 13 |
| Related Headache, Dose 3 | 0 | 135 |
| Any Myalgia, Dose 3 | 0 | 162 |
| Grade 3 Myalgia, Dose 3 | 0 | 26 |
| Related Myalgia, Dose 3 | 0 | 157 |
| Any Shivering, Dose 3 | 0 | 72 |
| Grade 3 Shivering, Dose 3 | 0 | 11 |
| Related Shivering, Dose 3 | 0 | 69 |
| Any Temperature, Dose 3 | 0 | 67 |
| Grade 3 Temperature, Dose 3 | 0 | 2 |
| Related Temperature, Dose 3 | 0 | 66 |
| Any Fatigue, Across doses | 253 | 228 |
| Grade 3 Fatigue, Across doses | 47 | 31 |
| Related Fatigue, Across doses | 236 | 216 |
| Any Gastrointestinal symptoms, Across doses | 114 | 84 |
| Grade 3 Gastrointestinal symptoms, Across doses | 12 | 7 |
| Related Gastrointestinal symptoms, Across doses | 100 | 77 |
| Any Headache, Across doses | 209 | 208 |
| Grade 3 Headache, Across doses | 29 | 24 |
| Related Headache, Across doses | 195 | 193 |
| Any Myalgia, Across doses | 257 | 225 |
| Grade 3 Myalgia, Across doses | 46 | 37 |
| Related Myalgia, Across doses | 245 | 218 |
| Any Shivering, Across doses | 137 | 99 |
| Grade 3 Shivering, Across doses | 25 | 15 |
| Related Shivering, Across doses | 131 | 95 |
| Any Temperature, Across doses | 112 | 96 |
| Grade 3 Temperature, Across doses | 1 | 3 |
| Related Temperature, Across doses | 108 | 91 |
The Co-Ad Group received only 2 vaccine doses, hence the number of participants for the Dose 3 categories in this group is 0.
| days | Co-Ad Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 3 (2 to 4) | 2 (1 to 3) |
| Any Pain, Dose 2 | 3 (2 to 4) | 3 (2 to 4) |
| Any Pain, Dose 3 | — | 3 (2 to 4) |
| Any Redness, Dose 1 | 3 (2 to 5) | 2 (1 to 3) |
| Any Redness, Dose 2 | 3 (2 to 4) | 3 (2 to 5) |
| Any Redness, Dose 3 | — | 3 (2 to 4) |
| Any Swelling, Dose 1 | 3 (2 to 5) | 2 (1 to 3) |
| Any Swelling, Dose 2 | 3 (2 to 4) | 4 (2 to 5) |
| Any Swelling, Dose 3 | — | 3 (2 to 5) |
| Any Fatigue, Dose 1 | 2 (1 to 4) | 2 (1 to 4) |
| Any Fatigue, Dose 2 | 2 (1 to 3) | 2 (1 to 3) |
| Any Fatigue, Dose 3 | — | 2 (1 to 3) |
| Any Gastrointestinal, Dose 1 | 2 (1 to 2.5) | 2 (1 to 3) |
| Any Gastrointestinal, Dose 2 | 2 (1 to 3) | 2 (1 to 3) |
| Any Gastrointestinal, Dose 3 | — | 2 (1 to 2) |
| Any Headache, Dose 1 | 2 (1 to 3) | 2 (1 to 2) |
| Any Headache, Dose 2 | 2 (1 to 3) | 2 (1 to 2.5) |
| Any Headache, Dose 3 | — | 2 (1 to 2) |
| Any Myalgia, Dose 1 | 2 (2 to 4) | 2 (1 to 3) |
| Any Myalgia, Dose 2 | 2 (1 to 3) | 2 (1 to 3.5) |
| Any Myalgia, Dose 3 | — | 2 (2 to 3) |
| Any Shivering, Dose 1 | 1 (1 to 2) | 2 (1 to 2) |
| Any Shivering, Dose 2 | 1 (1 to 2) | 1 (1 to 2) |
| Any Shivering, Dose 3 | — | 1 (1 to 2) |
| Any Temperature (Oral), Dose 1 | 1 (1 to 2) | 1 (1 to 2) |
| Any Temperature (Oral), Dose 2 | 1 (1 to 2) | 1 (1 to 2) |
| Any Temperature (Oral), Dose 3 | — | 1 (1 to 2) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Subjects with any AE(s) | 132 | 140 |
| Subjects with grade 3 AE(s) | 16 | 28 |
| Subjects with related AE(s) | 34 | 28 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Subjects with any SAE(s) | 7 | 9 |
| Fatal SAEs | 0 | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Subjects with any SAE(s) | 10 | 10 |
| Fatal SAE(s) | 2 | 2 |
| Related SAE(s) | 2 | 2 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Any pIMDs | 0 | 1 |
| Related pIMDs | 0 | 0 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End] | 1 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-Ad Group | 2/432 (0.5%) | 17/432 (3.9%) | 400/432 (92.6%) |
| Control Group | 5/433 (1.2%) | 19/433 (4.4%) | 393/433 (90.8%) |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 3/432 | 1/433 |
| PneumoniaInfections and infestations | 1/432 | 3/433 |
| Atrial fibrillationCardiac disorders | 2/432 | 1/433 |
| Cardiac failure congestiveCardiac disorders | 1/432 | 2/433 |
| Chest painGeneral disorders | 0/432 | 2/433 |
| Cerebral infarctionNervous system disorders | 0/432 | 2/433 |
| TachycardiaCardiac disorders | 1/432 | 0/433 |
| Gastric ulcerGastrointestinal disorders | 1/432 | 0/433 |
| AstheniaGeneral disorders | 1/432 | 0/433 |
| SarcoidosisImmune system disorders | 1/432 | 0/433 |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| PainGeneral disorders | 372/432 | 357/433 |
| MyalgiaMusculoskeletal and connective tissue disorders | 257/432 | 227/433 |
| FatigueGeneral disorders | 253/432 | 228/433 |
| ErythemaGeneral disorders | 234/432 | 194/433 |
| HeadacheNervous system disorders | 210/432 | 209/433 |
| ChillsGastrointestinal disorders | 137/432 | 99/433 |
| SwellingGeneral disorders | 137/432 | 115/433 |
| Gastrointestinal disorderGastrointestinal disorders | 114/432 | 84/433 |
| PyrexiaGeneral disorders | 112/432 | 97/433 |
| Age, Continuous(Years) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Mean | 63.2 ± 8.4 | 63.2 ± 8.4 | 63.2 ± 8.4 |
| Sex: Female, Male(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Female | 264 | 252 | 516 |
| Male | 168 | 181 | 349 |
| Race/Ethnicity, Customized(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| White - Caucasian / European Heritage | 408 | 406 | 814 |
| African Heritage / African American | 12 | 9 | 21 |
| American Indian or Alaskan Native | 1 | 3 | 4 |
| Asian - East Asian Heritage | 3 | 7 | 10 |
| Asian - Japanese Heritage | 0 | 1 | 1 |
| Asian - South East Asian Heritage | 4 | 2 | 6 |
| White - Arabic / North African Heritage | 2 | 0 | 2 |
| Mixed Origin | 2 | 5 | 7 |
Ran from Mar 2014 to primary completion in Jul 2015, 15 months.
Results were first posted in Jul 2017, 2 years after primary completion. A results delay was requested in Nov 2015.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 15 months is close to that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix